Document Detail


Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.
MedLine Citation:
PMID:  22997212     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In resource-limited settings, mothers infected with human immunodeficiency virus type 1 (HIV-1) face a difficult choice: breastfeed their infants but risk transmitting HIV-1 or not breastfeed their infants and risk the infants dying of other infectious diseases or malnutrition. Recent results from observational studies and randomized clinical trials indicate daily administration of nevirapine to the infant can prevent breast-milk HIV-1 transmission.
METHODS: Data from 5396 mother-infant pairs who participated in 5 randomized trials where the infant was HIV-1 negative at birth were pooled to estimate the efficacy of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Four daily regimens were compared: nevirapine for 6 weeks, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks.
RESULTS: The estimated 28-week risk of HIV-1 transmission was 5.8% (95% confidence interval [CI], 4.3%-7.9%) for the 6-week nevirapine regimen, 3.7% (95% CI, 2.5%-5.4%) for the 14-week nevirapine regimen, 4.8% (95% CI, 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.0%-3.1%) for the 28-week nevirapine regimen (log-rank test for trend, P < .001). Cox regression models with nevirapine as a time-varying covariate, stratified by trial site and adjusted for maternal CD4 cell count and infant birth weight, indicated that nevirapine reduces the rate of HIV-1 infection by 71% (95% CI, 58%-80%; P < .001) and reduces the rate of HIV infection or death by 58% (95% CI, 45%-69%; P < .001).
CONCLUSIONS: Extended prophylaxis with nevirapine or with nevirapine and zidovudine significantly reduces postnatal HIV-1 infection. Longer duration of prophylaxis results in a greater reduction in the risk of infection.
Authors:
Michael G Hudgens; Taha E Taha; Saad B Omer; Denise J Jamieson; Hana Lee; Lynne M Mofenson; Charles Chasela; Athena P Kourtis; Newton Kumwenda; Andrea Ruff; Abubaker Bedri; J Brooks Jackson; Philippa Musoke; Robert C Bollinger; Nikhil Gupte; Michael C Thigpen; Allan Taylor; Charles van der Horst
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.     Date:  2012-09-20
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  56     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-11     Completed Date:  2013-06-19     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / administration & dosage*
Antibiotic Prophylaxis / methods*
Breast Feeding / statistics & numerical data
Female
HIV Infections / epidemiology,  prevention & control*,  transmission,  virology
HIV-1 / isolation & purification*
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*,  statistics & numerical data
Kaplan-Meier Estimate
Male
Milk, Human / virology*
Nevirapine / administration & dosage*
Risk Factors
Grant Support
ID/Acronym/Agency:
13-01 U48-CCU409660-09//PHS HHS; 22-09 U48-DP001944/DP/NCCDPHP CDC HHS; 26-04U48-DP000059-01/DP/NCCDPHP CDC HHS; 5 U50 PS022061-05/PS/NCHHSTP CDC HHS; 5-D43TW001039/TW/FIC NIH HHS; 5-R24 TW007988/TW/FIC NIH HHS; D43-TW0000/TW/FIC NIH HHS; P30-AI50410/AI/NIAID NIH HHS; R01AI34235/AI/NIAID NIH HHS; R01AI3857601A/AI/NIAID NIH HHS; R01AI45462/AI/NIAID NIH HHS; U50/CC0222061/CC/ODCDC CDC HHS
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 99DK7FVK1H/Nevirapine
Comments/Corrections
Comment In:
Clin Infect Dis. 2013 Jan;56(1):140-2   [PMID:  22997213 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hospital-Acquired Listeriosis Outbreak Caused by Contaminated Diced Celery--Texas, 2010.
Next Document:  Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada.